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Abstract
Human testicular germ cell tumours of adolescents and adults (TGCTs), including their precursor
lesion carcinoma in situ (CIS), show expression of a 1.5 kb alternative transcript of the platelet-
derived growth factor (PDGF) a-receptor gene. The so-called P2 promoter involved is located in
intron 12 and its activity was found to be mutually exclusive with activity of the classical promoter
(P1), which encodes the full-length receptor. The presence of the 1.5 kb transcript could be a
putative marker for the early molecular diagnosis of TGCTs. In order to validate the RT-PCR
approach, this study shows that not more than 100 transcripts are necessary to obtain positivity in
the test used; moreover, samples from TGCTs or CIS-containing tissues can be diluted many-fold
before resulting in false-negative findings. This study also shows that within TGCTs, as in TGCT-
derived cell lines, expression of the 1.5 kb transcript is differentiation-dependent and positively
correlated with expression of the embryonic transcription factor OCT-4/POU5F1. Furthermore,
the results indicate that in some non-TGCT cancers and cell lines the 1.5 kb transcript is also
expressed, but without concomitant OCT-4/POU5F1 expression. The 1.5 kb transcript is also
present in early B cells and derived leukaemias (B-ALL). In spite of similarities in chromosomal
location, down-regulation upon differentiation of TGCTs, and PDGF a-receptor and c-KIT (the
stem cell factor receptor) both being a tyrosine kinase receptor, no correlation was found between
activity of the P2 promoter of the PDGF a-receptor gene and expression of c-KIT. In conclusion,
the 1.5 kb transcript of the PDGF a-receptor is expressed in various cells and tissues, including
particular blood cells. Although this may hamper the use of this transcript as a marker for
malignancies in general, it does not appear to interfere with assays for the early detection of
TGCTs. Copyright # 2002 John Wiley & Sons, Ltd.
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Introduction
The platelet-derived growth factor (PDGF) can occur
as three dimeric isoforms, PDGF AA, AB, and BB.
Their biological function is dependent on binding to
either of the existing PDGF receptors (a and b, which
belong to the cell surface receptors of the protein-
tyrosine kinase superfamily. The PDGF a-receptor
has high affinity for both the A- and the B-chain,
while the PDGF b-receptor has high affinity for the
PDGF B-chain only [1,2]. PDGF has been implicated
in several physiological and pathological processes,
including embryogenesis and tumourigenesis [3–5].
Transcription from the PDGF a-receptor P1 promo-
ter, located upstream of exon 1, results in a messenger
of 6.4 kb, encoding the full-length receptor, as well as
in a 3.0 kb transcript, potentially encoding a dominant-
negative receptor isoform [6]. Besides the presence of
this classical promoter, we identified an alternative
promoter (P2), located in intron 12. From this pro-
moter, both a 1.5 kb and a 5.0 kb transcript can be
obtained, although no corresponding protein products
have yet been identified [6–8]. Expression of the 1.5 kb
and 5.0 kb transcripts has originally been found in
undifferentiated Tera-2 clone 13 cells, a cell line
derived from a non-seminomatous testicular germ cell
tumour. Upon differentiation of these cells, the P2
promoter activity was silenced, while the P1 promoter
became activated. Data from this cell line thus showed
exclusivity between P1 and P2 promoter activities [7].
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We previously studied a series of primary testicular
germ cell tumours of adolescents and adults (TGCTs)
for the presence of the different PDGF a-receptor
transcripts [6,8]. Histologically and clinically, these
tumours can be divided into seminomas and non-
seminomas [9]. While seminomas mimic early germ
cells, non-seminomas may show characteristics of early
development: they can be composed of embryonal
Table 1. Summary of the results on PDGF a-receptor transcripts, c-KIT and OCT-4 expression
a–R P1 a–R P2
mRNAs mRNAs
OCT-4 c-KIT
Samples # 6.4 kb 1.5 kb mRNA mRNA
In vivo
Testicular samples
Parenchyma: normal 4 + xa + +
atrophic 4 + xa nd nd
fibrotic 1 + x nd nd
with epididymitis 2 + x nd nd
Epidermoid cyst and 1 + x nd nd
adjacent parenchyma 1 + x nd nd
Lymphoma 16 + + nd nd
Leydig cell tumour and 8 + + nd nd
adjacent parenchyma 5 + x nd nd
TGCT-parenchyma: without CIS 15 + x + +
with CIS 41 + + + +
Seminoma 30 + + + +
Nonseminoma: EC 2 + + + +
TE 2 + xb x +
YS 2 + xb x +
YS xenograft 1 x x x nd
mixed 19 + + + +
Haematopoietic samples
Pheripheral blood: PBL 2 x + nd nd
total lymphocytes 2 x + nd nd
B-lymphocytes 2 x + nd nd
T-lymphocytes 2 x x nd nd
granulocytes 2 x x nd nd
monocytes 2 x x nd nd
EBV-B cells 5 x + nd nd
Stem cells 1 x x nd nd
0-ALL 1 x x nd nd
C-ALL 2 x x nd nd
Pre-B 3 x x nd nd
B-ALL 2 x + nd nd
PLL/CLL 3/5 x x nd nd
Multiple myeloma 2 x + nd nd
In vitro
Tera2 clone 13 undifferentiated x + + +
RA differentiated + x x +
S2 x x x x
Melanocytes x + x +
Melanoma cell lines: Mel 57 + + x +
1F6 + x x +
U1240 x x x +
Glioma cell lines: U251 + + x +
U1242 + + x +
U373 + + x x
ALL=acute lymphocytic leukemia (0-ALL=lymphoid progenitor cell leukemia; C-ALL=pre-pre-B cell leukemia; Pre-B=pre-B cell leukemia; B-ALL=early
B cell leukemia); a–R=PDGF a-receptor; a=positive after an extra 12 cycles; b=remained negative after an extra 12 cycles; CIS=carcinoma in situ; EBV-B
cells=Epstein Barr virus transformed B cells; EC=embryonal carcinoma; nd=not determined; PBL=peripheral blood; PLL/CLL=chronic lymphocytic and
promyelocytic leukemias (intermediate B cell leukemias); P1=promoter 1; P2=promoter 2; RA=retinoic acid; TE=mature teratoma; TGCT=testicular
germ cell tumours of adolescents and adults; YS=yolk sac tumour; #=number of samples tested.
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carcinoma (the undifferentiated component), teratoma
(the somatically differentiated component), yolk sac
tumour, and choriocarcinoma (the extra-embryonally
differentiated components). In concordance with the
findings in the Tera-2 clone 13 cells, we demonstrated
that embryonal carcinomas, but not teratomas, show
expression of the 1.5 kb transcript [6,8]. In addition,
seminomas and non-seminomas of mixed histology
were also found to be positive. Moreover, expression
was also detected in carcinoma in situ (CIS), being
the precursor of all TGCTs [10], while normal and
atrophic parenchyma, as well as semen, were negative
[6]. Based on these data, we have proposed that the
1.5 kb transcript of the PDGF a-receptor may be an
informative tool for the early diagnosis of TGCTs.
In vitro experiments using the Tera-2 clone 13 cells
indicated that activity of the PDGF a-receptor P2
promoter is regulated by OCT-4, a POU-domain
transcription factor that is expressed in undifferen-
tiated cells only [11]. Whether this also accounts for the
in vivo situation has not so far been investigated. In
addition, particular developmental stages of TGCTs,
including CIS and seminoma, express c-KIT, the stem
cell factor receptor [12–15]. c-KIT is also a tyrosine
kinase receptor, has structural similarities to the
PDGF a-receptor, and their relative genes are arrayed
in a 5k-PDGF a-receptor p c-KIT-3k tandem on human
chromosome 4, band q12 [16–18]. Interestingly, down-
regulation of c-KIT expression is found upon differentia-
tion of TGCTs, which suggests a possible correlation
between c-KIT expression and activity of the PDGF
a-receptor P2 promoter. We have therefore investigated
the possibility that expression of the P2-derived 1.5 kb
transcript might be associated with c-KIT expression.
To investigate further the applicability of the 1.5 kb
transcript of the PDGF a-receptor for the early
diagnosis of TGCTs, the sensitivity and specificity of
the proposed RT-PCR detection were studied. In
addition, to gain a better understanding of the possible
regulatory mechanisms involved in PDGF a-receptor
P2 promoter activation, expression of OCT-4 and
c-KIT was investigated in selected tumour samples
and in vitro cell cultures.
Materials and methods
Tissue samples
Directly following orchidectomy, representative parts
of the tumour and adjacent testicular parenchyma
(when available) were divided into two fractions: one
was snap-frozen in liquid nitrogen, while the other
was fixed in 4% buffered formalin and embedded in
paraffin for histological analysis. The tumours were
diagnosed according to the World Health Organisation
classification for testicular tumours [19]. The samples
included are listed in Table 1.
Peripheral blood of two independent healthy volun-
teers was collected. One part was used, after lysis of
erythrocytes, to isolate the cells by centrifugation,
which were snap-frozen until use (designated as ‘total
peripheral blood sample’). The other fraction was
ficoll-purified, by which the lymphocytes/monocytes
(designated as ‘total lymphocyte sample’) were sepa-
rated from the erythrocyte/granulocyte fraction. The
granulocyte fraction was obtained from the latter after
blood lysis and centrifugation, and was also snap-
frozen. The lymphocytes were separated from the
monocytes by incubation for 2 h at 37uC in a Petri
dish, to which the monocytes specifically attach. The
medium was subsequently used to isolate the lympho-
cytes, whereas the monocytes were isolated by trypsi-
nization and snap-frozen. The B- and T-cells present in
the lymphocyte fraction were separated from each
other as follows: the sample was treated with AET-
treated sheep red blood cells (E-rosette test) and
ficoll purification, at the end of which both fractions
obtained were snap-frozen (Figure 4B).
CD34-positive haematopoietic stem cells were kindly
provided by Dr R. Torensma (Department of Tumor
Immunology, University Medical Center St. Radboud,
Nijmegen, The Netherlands). The cells were isolated
from a mononuclear fraction of normal bone marrow
using CD34-coated magnetic beads (Dynal). The cells
were detached, immunostained with a CD34 mono-
clonal antibody (HPCA 2; Becton & Dickinson, PE
labelled), and subsequently the CD34-positive fraction
was sorted with a Coulter Elite flow cytometer. This
fraction was 99% pure.
Haematopoietic malignancies were kindly provided
by Dr I. Touw (Department of Haematology, Erasmus
University, Rotterdam, The Netherlands) and are
listed in Table 1. All samples, except the multiple
myelomas, were purified to obtain highly enriched
populations of malignant cells as described before
[20,21]. Routinely Epstein–Barr virus (EBV)-infected B
cells (n=5) were kindly provided by Dr H. Dolstra
(Department of Haematology, University Medical
Center St. Radboud, Nijmegen, The Netherlands).
Cell culture
Tera-2 clone 13 cells were cultured and differentiated
by treatment with retinoic acid (RA) as previously
described [7]. S2 cells were cultured similarly to the
undifferentiated Tera-2 clone 13 cells.
RNA extraction and cDNA synthesis
Total RNA was isolated from sections of the frozen
tissues and snap-frozen cells using RNA-STAT-602
according to the supplier’s protocol (Tel-Test ‘B’ Inc.).
Parallel sections of the tissues were used for detailed
histological analysis as previously described [7]. Total
RNA was similarly isolated from the TGCT cell
lines. Melanocyte total RNA, isolated from a routinely
grown primary culture using the RNeasy mini kit
(Qiagen), was kindly provided by Dr N. Smit (Depart-
ment of Dermatology, Academic Hospital, Leiden, The
Netherlands). Total RNA from the Mel 57 and 1F6
cell lines [22] was kindly provided by Dr William
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Leenders. Poly(A+) RNA isolated from U-1240 MG,
U-251 MGsp, U-1242 MG, and U-374 MG malignant
glioma cell lines [23] was kindly provided by Dr Ester
Piek (Ludwig Institute for Cancer Research, Uppsala,
Sweden). Poly(A+) RNA from CD34-positive haema-
topoietic stem cells was isolated using the Micro-Fast
Track Isolation Kit as recommended (Invitrogen).
cDNA was synthesized using Expand RT (Boehringher
Mannheim) according to the supplied protocol.
Polymerase chain reaction (PCR)
The expression of the various genes, in the tissue
samples, cell fractions, and cell lines, was determined
by PCR amplification of the generated cDNA, using
gene or transcript-specific primer combinations span-
ning intron sequences. The following primers and
annealing temperatures were used: c-KIT sense: 5k-
CTG AAC ACG CAC CTG CTG AA-3k; c-KIT
antisense: 5k-AAG CTA CGT TGC TAT TGG GAA
T-3k (60uC); OCT-4 sense: 5k-ACA CCT GGC TTC
GGA TTT CG-3k; OCT-4 antisense: 5k-GGC GAT
GTG GCT GAT CTG CT-3k (62uC); for the PDGFa-
receptor P1-promoter-derived 6.4 kb transcript, the
following were used: exon-12 sense: 5k-GAC CCG
ATG CAG CTG CCT TA-3k and exon-17 antisense:
5k-AAC TCC ATT CCT CGG GCA ACT-3k (62uC);
for the P2-promoter-derived 1.5 kb transcript the
following were used: intron-12 sense: 5k-AAT GAT
TCT GCC TGC CCA CAG-3k and teratocarcinoma
cryptic exon (TCCE) antisense: 5k-GAC TCA GGT
TCC TCT GAC ATC TCG-3k (66uC); for the P1
promoter-derived 3.0 kb transcript, exon-12 sense
and TCCE antisense (62uC) were used; for the P2
promoter-derived 5.0 kb transcript, intron-12 sense and
exon 17 antisense (66uC) were used [6]. HPRT RT-
PCR was performed as a control for the quality of the
cDNAs tested, using primers previously designated as
244 and 246 [24]. A negative control, in which cDNA
was omitted, was used in every PCR assay. After an
initial denaturation of 4 min at 94uC, the samples were
amplified for 22–32 cycles (consisting of denaturation
for 1 min at 94uC, annealing for 1 min as specified
above, and an extension for 1 min at 72uC) and a final
extension of 7 min at 72uC. Some samples were
additionally boosted for 12 more cycles. The PCR
was performed in a final volume of 25 ml containing
100 ng of each primer, 0.2 mM dNTPs, 1.5 mM MgCl2
(except for the 6.4 kb PDGFa-receptor transcript, for
which 2 mM MgCl2 was used), and 1 U of Taq
polymerase (Gibco BRL) in recommended buffer. In
order to avoid detection interference by intron-less
OCT-4-related genomic sequences [25], the RT-PCR
analysis for OCT-4 expression was performed on
DNase-treated RNA as described before [26]. In
addition, the obtained PCR-amplified samples were
subsequently identified by an Apa-I restriction diges-
tion, which positively discriminates the OTF3A-derived
transcript, harbouring such a restriction site, from the
OTF3-related, Apa-I negative sequences (C. E. P. van
Roozendaal, unpublished). The PCR products gener-
ated were subsequently analysed on an ethidium
bromide-stained 1.5% agarose gel by UV exposure.
Sensitivity of the amplification method for the
1.5 kb transcript
The S2 cell line is found to be negative for all the
PDGF a-receptor transcripts, even after extensive
booster amplification (not shown). Therefore, 105,
104, 103, 102, 101, and 100 products obtained by PCR
using the 1.5 kb transcript-specific primers (see above)
on cDNA isolated from undifferentiated Tera-2 clone
13 cells were diluted in cDNA obtained from 250 ng of
S2 cell RNA and used for PCR. The Tera-2-derived
amplification products were checked by sequencing
before they were used for the dilution experiments. In
addition, undifferentiated Tera-2 clone 13 cells (101,
102, 103, 104, and 105, respectively) were diluted in
105 S2 cells, after which RNA was isolated, cDNA
was prepared, and RT-PCR was applied. Samples
with a known amount of transcripts were included as
controls.
Additionally, the sensitivity of the amplification
strategy was determined using serial dilutions (1 : 5,
1 : 10, 1 : 25, and 1 : 50) of RNA isolated from two
seminomas, two embryonal carcinomas, and two CIS-
containing parenchyma samples (80% of the tubules
contained CIS) in RNA derived from S2 cells.
Results
PDGF a-receptor 1.5 kb transcript: sensitivity of
detection method and expression in TGCTs
The 1.5 kb transcript of the PDGF a-receptor is present
in undifferentiated Tera-2 clone 13 cells [6,7], but not
in a cell line designated S2 (Table 1), which is most
likely not derived from a TGCT [27], as reported origi-
nally [28]. In our initial study, we applied 32 amplifi-
cation cycles on 250 ng of RNA input, associated with
approximately 4.0r104 cells [6]. We thus serially
diluted known concentrations of 1.5 kb transcript-
specific amplification products in cDNA of S2
obtained from 250 ng of RNA. After 22 amplification
cycles, 105 and 104 specific transcripts were required
for visualization, while after 32 cycles, as few as 100
transcripts could be detected (Figure 1A). Dilution
experiments of undifferentiated Tera-2 clone 13 cells in
samples of S2 cells indicated that one Tera-2 clone 13
cell per 1000 S2 cells was required for detection
(Figure 1B). This means that on average, a single
1.5 kb transcript is present in these cells. Based on
these findings, we applied 32 amplification cycles in the
experiments described further in this study, except
where otherwise indicated.
The 1.5 kb transcript has been found in different
histological types of TGCTs (with the exception of
pure teratoma [8]), as well as in CIS-containing
testicular parenchyma [6]. To assess the sensitivity of
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our detection method in tissue samples, the effect of
dilution of tumour cells was studied. cDNA from
TGCTs and testicular parenchyma samples containing
different amounts of CIS (20%, 50%, and 80% of the
seminiferous tubules) was initially analysed. In accor-
dance with previous studies, all seminomas, embryonal
carcinomas, and parenchyma samples containing CIS
were positive, whereas pure teratomas and yolk sac
tumours were negative (Table 1 and Figures 2A and
2B), even after a booster amplification of an additional
12 cycles (not shown). The absence of the 1.5 kb
transcript in yolk sac tumour is novel and was
confirmed by analysis of a yolk sac tumour xenograft,
derived from a mixed non-seminoma (Table 1 and
Figure 2C). On normal and atrophic testicular par-
enchyma, weak positivity was observed only after a
booster of an extra 12 cycles (see Table 1 and below).
Subsequently, serial dilutions of RNA from semino-
mas, embryonal carcinomas, and CIS-containing testi-
cular parenchyma (80% of the tubules contained CIS)
in RNA from S2 cells were performed. The results
(Figure 3) indicate that the 1.5 kb transcript can still be
detected in both seminomas and in one of the
embryonal carcinomas tested after a 1 : 50 dilution.
The other embryonal carcinoma still showed positivity
in a dilution of 1 : 25. The CIS-containing parenchyma
samples (with 80% of the seminiferous tubules positive
for CIS) could be diluted 10–25 times without losing
positivity.
All testicular samples expressed the 6.4 kb transcript
of the PDGF a-receptor (Table 1 and Figure 2A), in
contrast to the results from the Tera-2 cell line, which
can be explained by the presence of host tissue in the in
vivo samples, and possibly by heterogeneity of the
tumour cells themselves.
Specificity of the PDGF a-receptor 1.5 kb transcript
for TGCTs using in vivo samples
A series of testicular non-malignant lesions was
investigated (see Table 1), showing no positivity, while
both lymphomas and Leydig cell tumours contained
the transcript.
Total peripheral blood was subsequently tested for
the various PDGF a-receptor transcripts and found to
be weakly positive for the 1.5 kb transcript (Table 1
and Figure 4A). To determine the origin of this
positivity, different enriched sub-populations were
investigated (see Figure 4B and the Materials and
methods section), of which the B-cell-containing frac-
tion was positive (Table 1 and Figure 4A). None of the
samples showed expression of the 6.4 kb transcript
(Table 1 and Figure 4A). Moreover, EBV-transformed
B cells were also positive for the 1.5 kb transcript
(Table 1). To substantiate these findings further,
several haematological malignancies reflecting various
stages of B-cell development were tested (see Table 1
and Figure 5). No 6.4 kb transcripts were found in any
of the samples. B-ALL samples, representative of
the early B-cell stage, were exclusively positive for the
1.5 kb transcript. Two myelomas, representative of the
plasma cell stage, were also found to be positive, which
might be explained by the fact that these samples had
not been purified (see the Materials and methods
section). The results confirmed the previous finding of
co-expression of the 1.5 kb and 5.0 kb transcripts, as
Figure 1. Analysis of the sensitivity of the RT-PCR amplification method used to detect the 1.5 kb transcript of the PDGF a-receptor.
(A) Purified, sequence-verified, 1.5 kb transcript amplification products derived from the cell line Tera-2 clone 13 were diluted in
cDNA from the S2 cell line, known to lack this specific transcript (see Table 1). (B) Thirty-two amplification cycles for the 1.5 kb
transcript were used to detect undifferentiated Tera-2 clone 13 cells in a background of (non-expressing) S2 cells
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Figure 2. (A) Representative results of the detection of the 6.4 kb and 1.5 kb transcripts of the PDGF a-receptor, c-KIT and OCT-4
expression in normal testicular parenchyma (Testis), testicular parenchyma without CIS adjacent to a seminoma (TestisxCIS),
testicular parenchyma with CIS adjacent to a non-seminoma (Testis+CIS), a seminoma (SE), an embryonal carcinoma (EC), a yolk
sac tumour (YS), and a teratoma (TE). (B) Results of the detection of the 1.5 kb transcript of the PDGF a-receptor in testicular
parenchyma with 20%, 50%, and 80% CIS-containing seminiferous tubules, seminoma (SE), embryonal carcinoma (EC), and normal
testicular parenchyma (Testis) after 32 amplification cycles. All experiments were carried out in duplicate (not shown) on two
independent cases. (C) Results of the detection of the 1.5 kb transcript of the PDGF a-receptor in a primary mixed non-seminoma
(Tumour), containing embryonal carcinoma, teratoma and yolk sac tumor components, and absence of detection in a derived
xenograft only composed of yolk sac tumour (Xeno)
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well as of the 3.0 kb and 6.4 kb transcripts (Table 1
and Figure 4A).
Expression of PDGF a-receptor transcripts in
melanocytes, melanoma, and glioma cells
Expression of the PDGF a-receptor transcripts was also
studied in primary melanocytes, and melanoma and
glioma cell lines (Table 1 and Figure 6), which show
expression of c-KIT (see below). While three out of
the four glioma cell lines (U251, U1242, U373) and the
normal melanocyte primary culture expressed the
1.5 kb transcript, of the two melanoma cell lines only
Mel 57 showed positivity. The 6.4 kb transcript was
present in both melanoma cell lines, but not in normal
melanocytes, and in all glioma cell lines with, again,
the exception of U1240. The co-expression of the
1.5 kb and 6.4 kb transcripts is a novel finding, and
since it is found in cell lines, this cannot be due to
histological heterogeneity. Expression of the 1.5 kb
transcript in normal melanocytes again indicates that
the 1.5 kb transcript is not a tumour cell-specific
marker.
Correlation between PDGF a-receptor 1.5 kb
transcripts, OCT-4, and c-KIT expression
We investigated OCT-4 expression in both our in vivo
and in vitro samples. A direct correlation was observed
between expression of the 1.5 kb transcript and OCT-4
in TGCTs (Table 1 and Figure 2A). This is in contrast
to the non-TGCT cell lines and melanocyte primary
culture (Table 1 and Figure 6). Moreover, normal
testicular parenchyma showed OCT-4 expression, but
Figure 3. Results of the detection of the 1.5 kb transcript of the PDGF a-receptor in serially diluted RNA derived from two
seminomas (SE), two embryonal carcinomas (EC), and two samples of testicular parenchyma with 80% CIS-containing seminiferous
tubules
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Figure 4. (A) Results of the detection of all transcripts of the PDGF a-receptor (1.5, 3.0, 5.0, and 6.4 kb) by means of RT-PCR on
RNA isolated from total peripheral blood (PBL) and different enriched cell populations. (B) Schematic representation of the
purification strategy used to enrich specific cell populations from normal peripheral blood, i.e. B- and T-lymphocytes, granulocytes,
and monocytes (see the Materials and methods section for more details)
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Figure 5. Schematic representation of the detection of the 1.5 kb transcript of the PDGF a-receptor in haematopoietic malignancies
representative of different developmental stages of the B cell (upper panel). The compartment in which the cells are normally
situated is indicated. In addition, their malignant counterparts are shown (lower panel), which can be found in either compartment
Figure 6. Representative results of the detection of the 6.4 kb and 1.5 kb transcripts of the PDGF a-receptor, expression of c-KIT and
OCT-4. Shown are haematopoietic stem cells (CD34+), normal melanocytes, two cell lines derived from melanomas, and three from
gliomas
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did not express the 1.5 kb transcript (Table 1 and
Figure 2A).
The finding that most of the tissue samples and cell
lines, both malignant and non-malignant, show expres-
sion of c-KIT irrespective of the presence or absence
of the 1.5 kb transcript (Table 1 and Figures 2A and
6) indicates that there is not a common regulatory
mechanism that drives expression from c-KIT and the
P2 promoter of the PDGF a-receptor gene.
Discussion
We proposed the 1.5 kb transcript of the PDGF
a-receptor as an informative parameter for the early
diagnosis of TGCTs [6,8], the most common malig-
nancy in Caucasian adolescent and adult males [29].
This was based on the finding that no expression was
detected in normal and atrophic testicular parenchyma
and semen, while it was detectable in testicular
parenchyma containing CIS and in invasive TGCTs
[6,8]. In vitro experiments showed that expression is
differentiation-dependent [6–8]. Our results confirm
that this regulation is also present in primary TGCTs.
The dilution experiments indicate that for positivity,
at least 100 copies of this transcript are required within
a single experiment, consisting of 32 cycles with a total
input of 250 ng of RNA. This was found to correlate
with approximately 100 Tera-2 clone 13 cells, meaning
that on average a single 1.5 kb transcript is present in
these cells. The calculated single transcript per cell is,
however, probably an underestimate, because Tera-2
clone 13 cells are known to differentiate spontaneously,
thereby losing the 1.5 kb transcript [7]. We have shown
here that RNA isolated from seminomas and embry-
onal carcinomas can be diluted at least 25 times
without losing positivity. In addition, our results
indicate that positivity is still found when fewer than
10% of the seminiferous tubules included in the
samples under investigation contain CIS.
To assess specificity, we investigated a series of
testicular non-TGCT lesions, as well as samples of the
parenchyma of normal and atrophic testis. In accor-
dance with our earlier findings [6,8], no expression of
the 1.5 kb transcript was found in non-malignant
testicular lesions, or in testicular parenchyma without
CIS. The observation that 1.5 kb transcripts can be
detected, using additional cycles, in normal and
atrophic testicular parenchyma samples is most likely
related to our finding that at least a subfraction of B
cells, i.e. early B cells, express the transcript. The early
B cells can in fact indeed be found both in the
bone marrow and in the circulating lymphocyte pool,
representing a small fraction of the circulating B-cell
pool. Our investigation of 1.5 kb transcript expression
in haematopoietic malignancies suggests that it might
be restricted to specific steps during normal B-cell
development, being present at the early B-cell stage,
of which B-ALL leukaemic cells are representative
(Figure 5). Moreover, EBV-transformed B cells were
also found to be positive for the 1.5 kb transcript
and it is noteworthy that CD21, which is expressed
on B-ALL and early B cells, is required for EBV
transformation [30]. All primary testicular lymphomas
and Leydig cell tumours were also positive. Because of
the clear presence of the 1.5 kb transcript, the relatively
low level of expression in early B cells and the absence
of a correlation between positivity of the sample after
32 amplification cycles and the presence of lympho-
cytes, it is highly likely that the positivity found is
mainly due to the presence of the transcript in the
tumour cells, as supported by our in vitro data (see
below).
We demonstrated that some glioma and melanoma
cells, as well as normal melanocytes, showed expres-
sion of the 1.5 kb transcript. These samples also
expressed the 5.0 kb transcript of the PDGF a-receptor,
and the samples showing expression of the 6.4 kb
transcript also showed positivity for the 3.0 kb trans-
cript, as found before [6–8]. These data indicate that
co-expression of the 1.5 kb and 5.0 kb transcripts from
the P2 promoter and the 3.0 kb and 6.4 kb transcripts
of the P1 promoter is independent of the cell of origin.
Although it was originally found that the activities of
the P1 and P2 promoters were mutually exclusive [6,8],
it is now shown that both promoters can be active
simultaneously. The mutual exclusivity of the P1 and
P2 promoter activities observed in the undifferent-
iated versus differentiated Tera-2 cells is therefore
most likely to be due to a different availability of
differentiation-specific transcription factors. Our results
do not support the model that activity of the P2
promoter might be associated with expression of the
nearby c-KIT.
In vitro experiments showed that activity of the
PDGF a-receptor P2 promoter is dependent on the
POU-domain transcription factor OCT-4 [11]. This
also holds true in TGCTs, because all components that
are positive for the 1.5 kb transcript also express OCT-4,
while both teratomas and yolk sac tumours are
negative for the 1.5 kb transcript, as well as for OCT-
4. Noteworthy is the finding that loss of OCT-4 from
mouse embryonic stem cells prevents them from
forming somatic tissues, and that their differentiation
is consequently restricted to the trophoblastic lineage
[31]. Indeed, human yolk sac tumours were found to be
negative for OCT-4 (this study). Our results show,
however, that expression of OCT-4 is not necessary or
sufficient to activate the P2 promoter: 1.5 kb trans-
cripts can even be found without expression of OCT-4.
From these data it appears likely that P2 transcript
expression in TGCTs is driven by OCT-4, in coopera-
tion with other transcription factors. It remains to be
investigated which other members of the large OCT
family are involved in regulation of the P2 promoter in
non-TGCT cells.
This study has demonstrated that expression of the
1.5 kb transcript, i.e. activity of the PDGF a-receptor
P2 promoter, is not restricted to TGCTs, but can be
found in a number of malignant and non-malignant
476 C. Palumbo et al.
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tissues and cells. At least two mechanisms seem to
regulate P2 promoter activity, one partially OCT-4-
dependent, which is found in embryonal tissues and
derived tumours, and one completely independent of
OCT-4. The present data validate the usefulness of
detection of the 1.5 kb transcript for the early
diagnosis of TGCTs, and possibly of other testicular
malignancies, such as lymphomas and Leydig cell
tumours. It must, however, be performed in a well-
controlled set-up, in which the presence of contaminat-
ing early B cells is reduced as much as possible.
Acknowledgements
We would like to thank the urologists and pathologists in the
south-western part of The Netherlands for their support in
collecting the testicular lesions, Dr Ester Piek for providing
RNA from the glioma cell lines, Dr N. Smit for RNA from
melanocytes, Dr William Leenders for RNA from the melanoma
cell lines, Dr Torensma for the haematopoietic stem cells, Dr
Dolstra for the EBV-infected B cells, and Dr Ivo Touw for the
samples of the haematological malignancies. This work was
financially supported by the Dutch Cancer Society (KWF, grant
KUN 96-1364).
References
1. Heldin CH, Westermark B. Platelet-derived growth factor: three
isoforms and two receptor types. Trends Genet 1989; 5: 108–111.
2. Seifert RA, Hart CE, Phillips PE, et al. Two different subunits
associate to create isoform-specific platelet-derived growth factor
receptors. J Biol Chem 1989; 264: 8771–8778.
3. Ross R, Bowen-Pope DF, Raines EW. Platelet-derived growth
factor and its role in health and disease. Philos Trans R Soc
London Ser B Biol Sci 1990; 327: 155–169.
4. Bowen-Pope DF, Van Koppen A, Schatteman G. Is PDGF
really important? Testing the hypotheses. Trends Genet 1991;
7: 413–418.
5. Westermark B, Heldin CH. Platelet-derived growth factor.
Structure, function and implications in normal and malignant
cell growth. Acta Oncol 1993; 32: 101–105.
6. Mosselman S, Looijenga LHJ, Gillis AJM, et al. Aberrant
platelet-derived growth factor a-receptor transcript as a diag-
nostic marker for early human germ cell tumors of the adult
testis. Proc Natl Acad Sci U S A 1996; 93: 2884–2888.
7. Mosselman S, Claesson-Welsh L, Kamphuis JS, Van Zoelen EJJ.
Developmentally regulated expression of two novel platelet-
derived growth factor a-receptor transcripts in human terato-
carcinoma cells. Cancer Res 1994; 54: 220–225.
8. Oosterhuis JW, Gillis AJM, Van Roozendaal CEP, Van Zoelen
EJJ, Looijenga LHJ. The platelet-derived growth factor a-
receptor 1.5 kb transcript: target for molecular detection of
testicular germ cell tumours of adolescents and adults. APMIS
1998; 106: 207–215.
9. Mostofi FK, Sesterhenn IA, Davis CJJ. Immunopathology of
germ cell tumors of the testis. Semin Diagn Pathol 1987;
4: 320–341.
10. Skakkebæk NE. Possible carcinoma-in-situ of the testis. Lancet
1972; 2: 516–517.
11. Kraft HJ, Mosselman S, Smits HA, et al. Oct-4 regulates
alternative platelet-derived growth factor a receptor gene
promoter in human embryonal carcinoma cells. J Biol Chem
1996; 271: 12873–12878.
12. Strohmeyer T, Peter S, Hartmann M, et al. Expression of the
hst-1 and c-kit protooncogenes in human testicular germ cell
tumors. Cancer Res 1991; 51: 1811–1816.
13. Rajpert-De Meyts E, Skakkebæk NE. Expression of the c-kit
protein product in carcinoma-in-situ and invasive testicular germ
cell tumours. Int J Androl 1994; 17: 85–92.
14. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al.
Differential expression of the c-kit proto-oncogene in germ cell
tumours. J Pathol 1995; 177: 253–258.
15. Chou PM, Barquin N, Guinan P, Ridaura Sanz C, Gonzalez-
Crussi F. Differential expression of p53, c-kit, and CD34 in
prepubertal and postpubertal testicular germ cell tumors. Cancer
1997; 79: 2430–2434.
16. Spritz RA, Strunk KM, Lee ST, et al. A YAC contig spanning a
cluster of human type III receptor protein tyrosine kinase genes
(PDGFRA–KIT–KDR) in chromosome segment 4q12. Genomics
1994; 22: 431–436.
17. Gronwald RG, Adler DA, Kelly JD, Disteche CM, Bowen-
Pope DF. The human PDGF receptor alpha-subunit gene maps
to chromosome 4 in close proximity to c-kit. Hum Genet 1990;
85: 383–385.
18. Giebel LB, Strunk KM, Holmes SA, Spritz RA. Organiza-
tion and nucleotide sequence of the human KIT (mast/stem
cell growth factor receptor) proto-oncogene. Oncogene 1992;
7: 2207–2217.
19. Mostofi FK, Sesterhenn IA. Histological Typing of Testis
Tumours (2nd edn). Springer: Berlin, 1998; 132.
20. Touw I, Lowenberg B. Interleukin 2 stimulates chronic lympho-
cytic leukemia colony formation in vitro. Blood 1985; 66: 237–
240.
21. Touw I, Delwel R, Bolhuis R, van Zanen G, Lowenberg B.
Common and pre-B acute lymphoblastic leukemia cells express
interleukin 2 receptors, and interleukin 2 stimulates in vitro
colony formation. Blood 1985; 66: 556–561.
22. van Groningen JJ, Weterman MA, Swart GW, Bloemers HP.
Functional analysis of the human calcyclin gene promoter in a
panel of human melanoma cell lines. Biochem Biophys Res
Commun 1995; 213: 1122–1131.
23. Nister M, Libermann TA, Betsholtz C, et al. Expression of
messenger RNAs for platelet-derived growth factor and trans-
forming growth factor-alpha and their receptors in human
malignant glioma cell lines. Cancer Res 1988; 48: 3910–3918.
24. Gibbs RA, Ngyuen P-N, McBride LJ, Koepf SM, Caskey CT.
Identification of mutations leading to the Lesch–Nyhan syn-
drome by automated direct DNA sequencing of in vitro amplified
cDNA. Proc Natl Acad Sci U S A 1989; 86: 1919–1923.
25. Takeda J, Seino S, Bell GI. Human Oct3 gene family: cDNA
sequences, alternative splicing, gene organization, chromosomal
location, and expression at low levels in adult tissues. Nucleic
Acids Res 1992; 20: 4613–4620.
26. van Roozendaal CE, Gillis AJ, Klijn JG, et al. Loss of
imprinting of IGF2 and not H19 in breast cancer, adjacent
normal tissue and derived fibroblast cultures. FEBS Lett 1998;
437: 107–111.
27. Andrews PW, Casper J, Damjanov I, et al. A comparative
analysis of cell surface antigens expressed by cell lines derived
from human germ cell tumors. Int J Cancer 1996; 66: 806–816.
28. von Keitz AT, Riedmiller H, Neumann K, Gutschank W,
Fonatsch C. Establishment and characterization of a seminoma
cell-line (S2). Invest Urol 1994; 5: 28–31.
29. Adami HO, Bergstro¨m R, Mo¨hner M, et al. Testicular cancer in
nine northern European countries. Int J Cancer 1994; 59: 33–38.
30. Fearon DT, Ahearn JM. Complement receptor type 1 (C3b/C4b
receptor; CD35) and complement receptor type 2 (C3d/Epstein–
Barr virus receptor; CD21). Curr Top Microbiol Immunol 1990;
153: 83–98.
31. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of
pluripotent stem cells in the mammalian embryo depends on the
POU transcription factor Oct4. Cell 1998; 95: 379–391.
PDGF a-receptor transcripts, expression, and regulation 477
Copyright # 2002 John Wiley & Sons, Ltd. J Pathol 2002; 196: 467–477.
